United Therapeutics Corporation has announced a groundbreaking partnership with Intermountain Health, one of the nation's leading health systems. This collaboration marks a significant milestone as the first patient has been treated using a bioengineered liver support system, miroliverELAP®, at Intermountain Medical Center in Murray, Utah. This phase 1 clinical study aims to address the critical shortage of transplantable organs by investigating the use of this innovative external liver assist product for patients with acute liver failure. Both organizations express their commitment to pioneering advancements in medical care and improving patient outcomes through this joint effort.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250624852248) on June 24, 2025, and is solely responsible for the information contained therein.